Drug Profile
Cabazitaxel injection - AbbVie
Alternative Names: Cabazitaxel - AbbVieLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Allergan
- Developer AbbVie
- Class Amines; Antineoplastics; Benzene derivatives; Esters; Small molecules; Taxanes
- Mechanism of Action Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Prostate cancer
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 12 Dec 2018 Cabazitaxel injection is not yet available in USA for Prostate cancer (Allergan website, December 2018)
- 19 Aug 2015 Actavis receives tentative NDA approval of Cabazitaxel injection for Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA